OPKO Health Inc. (OPK)’s Financial Results Comparing With Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)

Since OPKO Health Inc. (NASDAQ:OPK) and Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OPKO Health Inc. 1.03B 1.58 298.50M -0.52 0.00
Marinus Pharmaceuticals Inc. N/A 0.00 31.35M -0.86 0.00

Demonstrates OPKO Health Inc. and Marinus Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
OPKO Health Inc. -28.98% -16% -11.4%
Marinus Pharmaceuticals Inc. 0.00% -65.6% -60.7%

Volatility and Risk

OPKO Health Inc. is 102.00% more volatile than S&P 500 due to its 2.02 beta. From a competition point of view, Marinus Pharmaceuticals Inc. has a 3.08 beta which is 208.00% more volatile compared to S&P 500.


OPKO Health Inc.’s Current Ratio is 0.9 while its Quick Ratio is 0.8. On the competitive side is, Marinus Pharmaceuticals Inc. which has a 5.9 Current Ratio and a 5.9 Quick Ratio. Marinus Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to OPKO Health Inc.

Analyst Ratings

The table given features the ratings and recommendations for OPKO Health Inc. and Marinus Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
OPKO Health Inc. 0 0 0 0.00
Marinus Pharmaceuticals Inc. 0 0 1 3.00

Meanwhile, Marinus Pharmaceuticals Inc.’s average target price is $10, while its potential upside is 190.70%.

Institutional and Insider Ownership

The shares of both OPKO Health Inc. and Marinus Pharmaceuticals Inc. are owned by institutional investors at 27.5% and 76.4% respectively. About 5.1% of OPKO Health Inc.’s share are held by insiders. Comparatively, Marinus Pharmaceuticals Inc. has 1.14% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OPKO Health Inc. -11.23% -13.99% -43.34% -19.61% -36.28% -32.24%
Marinus Pharmaceuticals Inc. 12.21% -1.13% -21.67% -28.02% -39.35% -35.78%

For the past year OPKO Health Inc.’s stock price has smaller decline than Marinus Pharmaceuticals Inc.


OPKO Health Inc. beats Marinus Pharmaceuticals Inc. on 6 of the 10 factors.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.